Glenmark Pharmaceuticals trades higher on the bourses

13 Jan 2016 Evaluate

Glenmark Pharmaceuticals is currently trading at Rs. 870.45, up by 20.90 points or 2.46% from its previous closing of Rs. 849.55 on the BSE.

The scrip opened at Rs. 863.00 and has touched a high and low of Rs. 876.00 and Rs. 849.95 respectively. So far 47890 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 1261.95 on 21-Aug-2015 and a 52 week low of Rs. 705.00 on 03-Feb-2015.

Last one week high and low of the scrip stood at Rs. 954.45 and Rs. 837.50 respectively. The current market cap of the company is Rs. 24533.65 crore.

The promoters holding in the company stood at 46.45% while Institutions and Non-Institutions held 42.81% and 10.75% respectively.

Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals (GPL), has discovered and initiation of IND-enabling studies for a novel clinical development candidate, GBR 1342.  GBR 1342 is a CD38xCD3 bi-specific antibody based on Glenmark’s proprietary BEAT platform. GBR 1342 is the second clinical development candidate (following GBR 1302 a HER2xCD3 bi-specific antibody) based on the BEAT technology. It is also Glenmark’s second clinical candidate targeting oncology indications.

CD38 is one of the few known markers for plasma cells and is a well-established target for multiple myeloma, a cancer caused by malignant plasma cells. CD38 is potentially also a target for other hematopoietic malignancies. GBR 1342’s mode of action is similar to GBR 1302, Glenmark’s first CD3 redirecting antibody. GBR 1342 redirects cytotoxic T cells through its CD3 binding arm onto CD38-expressing cancer cells and induces the killing of these cancer cells by the T cells. Glenmark is committed to moving GBR 1342 rapidly into clinical trials.

Glenmark Pharmaceuticals (GPL) is a research-driven, global, integrated pharmaceutical company headquartered in Mumbai, India. It is ranked among the top 80 Pharma & Biotech companies in the world in terms of revenues. Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity).

Glenmark Pharma Share Price

1965.75 -8.40 (-0.43%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×